Clinical characteristics, GAD antibody (GADA) and change of C-peptide in Korean young age of onset diabetic patients

Diabetic Medicine

Volumn 19, Issue 3, 2002, Pages 227-233

  Ahn, C W ^a   Kim, H S ^a   Nam, J H ^a   Song, Y D ^a   Lim, S K ^a   Kim, K R ^a   Lee, H C ^a   Huh, K B ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

C peptide; GADA; Korean; Type 1 diabetes; Type 2 diabetes; Young age onset diabetes

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIET RESTRICTION; DISEASE CLASSIFICATION; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; KETONURIA; KOREA; MAJOR CLINICAL STUDY; MALE; PREVALENCE;

ADOLESCENT; ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FASTING; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; KOREA; MALE;

EID: 0036229274     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00670.x     Document Type: Article

References (30)

1. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
2. Report of the expert committee on the diagnosis and classification of diabetes mellitus
3. UKPDS 25: Antibody to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin treatment in type 2 diabetes
4. Antibodies to GAD in elderly patients with previously diagnosed NIDDM
5. Identification of the 64 KD autoantigen in insulin-dependent diabetes as the GABA synthesizing enzyme glutamic acid decarboxylase
6. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus
7. Atypical diabetes in Koreans
8. Clinical characteristics of diabetes in Korea
9. Relationships among 64k autoantibodies, pancreatic beta-cell function, HLA-DR antigens and HLA-DQ genes in patients with insulin-dependent diabetes mellitus in Korea
10. Role of HLA class II alleles in Korean patients with IDDM diabetes
11. Non-insulin-dependent diabetes mellitus (NIDDM) in Korea
12. Comparative immunology of bovine, porcine and human proinsulins and C-peptides
13. Fasting serum C-peptide, glucagon, stimulated serum C-peptide and urinary C-peptide in clinical classification of diabetes
14. Clinical characteristics of Korean diabetic patients classified by fasting plasma C-peptide level and degree of obesity
15. The prevalence of micro- and macrovascular complications of Korean NIDDM patients
16. Classification of newly diagnosed diabetic patients as insulin requiring or non insulin requiring based on clinical and biochemical variables
17. Fasting plasma C-peptide glucagon stimulated plasma C-peptide and urinary C-peptide in relation to clinical type of diabetes
18. The meaning and use of the area under a receiver operating characteristic (ROC) curve
19. Prevalence of islet cell autoantibody and mitochondrial DNA mutation among typical and atypical type 1 diabetic patients in Korea
20. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis
21. Maleness as risk factor for slowly progressive IDDM
22. A comparison of childhood and adult type 1 diabetes mellitus
23. Clinical features of Korean diabetics under the age of 40 years
24. Some immunogenetic characteristics and clinical heterogeneity of young age onset insulin dependent diabetes mellitus in Korea
25. Difficulties in classifying diabetes at presentation in the young adult
26. Immunogenetic and nutritional profile in insulin-using youth-onset diabetics in Korea
27. C-peptide measurement and its clinical usefulness
28. C-peptide response to glucagon: A test for the residual β-cell function in diabetes mellitus
29. Prevalence of residual β-cell function and its metabolic consequences in type 1 diabetes
30. Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassificationable diabetes